Catalyst Biosciences has selected CB 813, a second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients.

Catalyst Biosciences has entered into an exclusive worldwide research and license agreement with Centocor Research & Development for Alterase therapeutics, a next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins.